Skip to main content Skip to main navigation menu Skip to site footer

Retrospective study on nasopharyngeal cancer (RENOCS): outcome management of in-hospital patients

  • Achmad Chusnu Romdhoni ,
  • Hayyu Fath Rachmadhan ,
  • Yufi Aulia Azmi ,
  • Faisal Yusuf Ashari ,
  • Astri Dewayani ,

Abstract

Link of Video Abstract: https://youtu.be/J6ZC8xzJB8M


Background:
Nasopharyngeal carcinoma (NPC) is distinct from other head and neck cancers in terms of epidemiology, clinical presentation, biological markers, carcinogenic risk factors, and prognostic factors. However, there is only a small amount of information available on NPC in Indonesia, where the recorded mean prevalence is 6.2/100,000 and there are 13,000 new cases reported annually. Numerous treatments are used, and it's important to pinpoint the risk factor that contributes to a poor prognosis. The aim of this study is to look at the outcomes of nasopharyngeal cancer patients who were hospitalized at a referral hospital based on their characteristics and laboratory results.

Methods: Data from medical records were analyzed to conduct a retrospective study. Up to 785 patients who were hospitalized at a single referral hospital from 2018 to 2022 and received a nasopharyngeal cancer diagnosis were included. Data were statistically and descriptively analyzed.

Results: Chronic kidney disease, education level, and tumor, node, metastasis (TNM) classification was associated with patient outcomes (p < 0.05). The results of the multivariate analysis showed that there were significant differences in the variables of chronic kidney disease and pre-treatment albumin levels. Therefore, people with nasopharyngeal cancer who have chronic kidney disease have a 12,151 chance of mortality.

Conclusion: In Indonesia, there is a critical need for efforts to identify NPC as early as possible. These should include public education to increase awareness of the comorbidity status, especially chronic kidney disease to prevent poor outcomes.

References

  1. Reffai A, Mesmoudi M, Derkaoui T, Ghailani Nourouti N, Barakat A, Sellal N, et al. Epidemiological profile and clinicopathological, therapeutic, and prognostic characteristics of nasopharyngeal carcinoma in Northern Morocco. Cancer Control. 2021;28:10732748211050588.
  2. Alotaibi AD, Ahmed HG, Elasbali AM. Nasopharyngeal cancer in Saudi Arabia: Epidemiology and possible risk factors. J Oncol Sci. 2019;5(1):23–30.
  3. Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia. Osong Public Heal Res Perspect. 2016;7(6):360–72.
  4. Yu H, Yin X, Mao Y, Chen M, Tang Q, Yan S. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019. Eur Arch Oto-Rhino-Laryngology. 2022;279(3):1519–33.
  5. Utomo AW, Romdhoni AC. Characteristics of patients with nasopharyngeal carcinoma in Dr. Soetomo General Academic Hospital Surabaya. Bali Medical Journal. 2023;12(2):1589-1593.
  6. Nuaba IGA, Weta IW, Suardana W, Wihandani DM, Supadmanaba IGP, Sari NNSP. CYP1A1 rs464903 increased the risk of undifferentiated type nasopharyngeal carcinoma among the Balinese population. Bali Medical Journal. 2023;12(1): 583-587.
  7. Sekarutami SM, Gondhowiardjo S, Yuliasti R, Syarifah L, Adham M. Survival of nasopharyngeal cancer in national referral hospital of Indonesia: A study on radiotherapy patients. Oral Oncol. 2020;106:104707.
  8. Dwijayanti F, Prabawa A, Besral, Herawati C. The five-year survival rate of patients with nasopharyngeal carcinoma based on tumor response after receiving neoadjuvant chemotherapy, followed by chemoradiation, in Indonesia: a retrospective study. Oncology. 2020;98(3):154–60.
  9. Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31(4):185-196.
  10. Lee A, Chow JCH, Lee NY. Treatment deescalation strategies for nasopharyngeal cancer: a review. JAMA Oncol. 2021;7(3):445–53.
  11. Assayag M, Rouvier P, Gauthier M, et al. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed. BMC Cancer. 2017;17(1):770
  12. Jia JB, Lall C, Tirkes T, Gulati R, Lamba R, Goodwin SC. Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective. Insights Imaging. 2015;6(4):479-487.
  13. Hutajulu SH, Howdon D, Taroeno-Hariadi KW, Hardianti MS, Purwanto I, Indrasari SR, et al. Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: a hospital-based retrospective study. PLoS One. 2021;16:1–20.
  14. Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer. 2013;13(1):226.
  15. Li J, Chen S, Peng S, et al. Prognostic nomogram for patients with nasopharyngeal carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci. 2018;14(5):549-556.
  16. Gao N, Yang RN, Meng Z, Wang WH. The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis. Biosci Rep. 2018;38(6):BSR20180686.
  17. Berardi R, Torniai M, Lenci E, Pecci F, Morgese F, Rinaldi S. Electrolyte disorders in cancer patients: a systematic review. J Cancer Metastasis Treat. 2019;5:79.
  18. Wedari NLPH, Budayanti NNS, Sukrama IDM, Mayura IPB. Implementation of antinuclear antibodies in autoimmune diagnostic tests: a literature review from immunological aspects. Journal of Clinical Microbiology and Infectious Diseases. 2022;2(2):27-30.
  19. Giannakeas V, Kotsopoulos J, Cheung MC, Rosella L, Brooks JD, Lipscombe L, et al. Analysis of platelet count and new cancer diagnosis over a 10-year period. JAMA Netw Open. 2022;5(1):e2141633–e2141633.
  20. Giannakeas V. Trends in platelet count among cancer patients. Exp Hematol Oncol. 2022;16–9.
  21. Chen YP, Chen C, Mai ZY, et al. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett. 2015;9(3):1458-1466.
  22. Rini FS, Murbawani EA, Fasitasari M, Puruhita N, Khairuddin. The relationship between nutritional status before chemotherapy with nutritional status after chemotherapy in locoregionally advanced nasopharyngeal carcinoma patients. Bali Medical Journal. 2023;12(1): 843-850.
  23. Sun J, Huang Z, Hu Z, Sun R. Benefits of local tumor excision and pharyngectomy on the survival of nasopharyngeal carcinoma patients: a retrospective observational study based on SEER database. J Transl Med. 2017;15(1):116.
  24. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9(1):69.
  25. Yang Z, Zheng Y, Wu Z, Wen Y, Wang G, Chen S, et al. Association between pre-diagnostic serum albumin and cancer risk: results from a prospective population-based study. Cancer Med. 2021;10(12):4054–65.
  26. Wang X, Han H, Duan Q, Khan U, Hu Y, Yao X. Changes of serum albumin level and systemic inflammatory response in inoperable non-small cell lung cancer patients after chemotherapy. J Cancer Res Ther. 2014;10(4).

How to Cite

Romdhoni, A. C., Hayyu Fath Rachmadhan, Yufi Aulia Azmi, Faisal Yusuf Ashari, & Astri Dewayani. (2023). Retrospective study on nasopharyngeal cancer (RENOCS): outcome management of in-hospital patients. Bali Medical Journal, 12(2), 1665–1671. https://doi.org/10.15562/bmj.v12i2.4512

HTML
40

Total
18

Share

Search Panel

Achmad Chusnu Romdhoni
Google Scholar
Pubmed
BMJ Journal


Hayyu Fath Rachmadhan
Google Scholar
Pubmed
BMJ Journal


Yufi Aulia Azmi
Google Scholar
Pubmed
BMJ Journal


Faisal Yusuf Ashari
Google Scholar
Pubmed
BMJ Journal


Astri Dewayani
Google Scholar
Pubmed
BMJ Journal